SteadyMed Ltd.

Submit Your Information

Company Name	SteadyMed Ltd.
Stock Symbol	STDY
Status	1

On August 31, 2017, SteadyMed announced that it received a Refusal to File letter from the FDA in connection with its New Drug Application (“NDA”) for Treyvent, a pulmonary arterial hypertension treatment. Based on a preliminary review of the NDA, which was submitted in June of 2017, the FDA determined that the application is not sufficiently complete to permit a substantive review.

On this news, SteadyMed's share price fell 33% on August 31, 2017, thereby injuring investors.

Submit Your Information

If you suffered a loss on your SteadyMed Ltd. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.

First Name*

Middle Initial

Last Name*

Email*

Phone*

If representing a Corporation, Trust, Partnership or other entity, Name of Entity

If representing an Entity, Position at Entity

Mailing Address

City

State/Province

ZIP/Postal Code

Country

Are you a current or former employee of the company?

Did you purchase any shares before November 30, -0001?

Shares Purchased

Number of Shares	Buy Date	Price Per Share	Add
Purchased quantity	Purchased month Purchased day Purchased year

Shares Sold

Number of Shares	Sell Date	Price Per Share	Add
	Sold month Sold day Sold year

Additional Comments